Polynovo
PolyNovo specializes in developing and commercializing advanced medical devices using its proprietary NovoSorb technology. The company focuses on treating burns, surgical wounds, and providing solutions for Negative Pressure Wound Therapy, positioning itself as a leader in innovative healthcare solutions.
Short position
Polynovo (ASX:PNV) has 7.06% of its shares on issue reported as short positions as of 5 Oct 2026, or about 48,746,700 shares. Over the past 30 days that figure has fallen 0.90 percentage points, and over 90 days it has fallen 1.54 percentage points. Its highest recorded short interest was 14.61% in May 2026. PNV is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Polynovo (PNV) company profile
Profile, insiders and operations
Company
AI-generated research profile of Polynovo
PNV intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links